Disease & disorder

melanoma

MONDO:0005105

A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.

Clinical trials454
Recruiting78
Drug concepts studied20
Synonyms4

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.

Medications under investigation

Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.

Loading mapped interventions…

MONDO disease family

Loading verified ontology relationships…

Recruiting studies by city

Loading research-site locations…

Trial status

Loading…

Trial phase

Loading…

Study start year

Loading…

Investigated drug interventions

Loading…
Background context

Melanoma

Melanoma is a type of cancer, typically skin cancer; it develops from the melanin-producing cells known as melanocytes. It typically occurs in the skin, but may rarely occur in the mouth, intestines, or eye (uveal melanoma). In very rare cases melanoma can also happen in the lung, which is known as primary pulmonary melanoma and only happens in 0.01% of primary lung tumors. In females, melanomas most commonly occur on the legs; while in males, on the back. Melanoma is frequently referred to as malignant melanoma. However, the medical community stresses that there is no such thing as a 'benign melanoma' and recommends that the term 'malignant melanoma' should be avoided as it is redundant. About 30% of melanomas develop from moles. Changes in a mole that can indicate melanoma include increase—especially rapid increase—in size, irregular edges, change in color, itchiness, or skin breakdown. The primary cause of melanoma is ultraviolet light (UV) exposure in those with low levels of the skin pigment melanin. The UV light may be from the sun or other sources, such as tanning devices. Those with many moles, a history of affected family members, and poor immune function are at greater risk. A number of rare genetic conditions, such as xeroderma pigmentosum, also increase the risk. Diagnosis is by biopsy and analysis of any skin lesion that has signs of being potentially cancerous. Avoiding UV light and using sunscreen in UV-bright sun conditions may prevent melanoma. Treatment typically is removal by surgery of the melanoma and the potentially affected adjacent tissue borderin...

Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With MelanomaNCT07476326 · 2026-09-09
RECRUITING
Intratumoral N17350 in Advanced Solid TumorsNCT07339176 · 2026-05-25
RECRUITING
Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support PersonsNCT07788729 · 2026-04-21
RECRUITING
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant TumorsNCT07552467 · 2026-04-01
RECRUITING
Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)NCT07524114 · 2026-03-31
RECRUITING
A Study of DXC014 in Patients With Advanced Solid Tumors.NCT07177937 · 2026-03-03
RECRUITING
Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsNCT07161310 · 2026-01-02
RECRUITING
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasNCT07285044 · 2025-12-18
RECRUITING
Promoting Immunotherapy Efficacy With Low-Dose Liver RTNCT07225036 · 2025-12-15
RECRUITING
The Florida ASCENT StudyNCT07042243 · 2025-12-05
RECRUITING
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid TumorsNCT07371663 · 2025-12-03
RECRUITING
Patient Preference for Subcutaneous vs. Intravenous Immune TherapyNCT07223424 · 2025-11-04
RECRUITING
VSV-02 Compassionate Use in Advanced Solid TumorsNCT07260591 · 2025-09-22
RECRUITING
DESTINY-PANTUMOUR04NCT07124000 · 2025-09-18
RECRUITING
Contrast-enhanced Ultrasound for Sentinel Node DetectionNCT07310758 · 2025-09-18
RECRUITING
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsNCT06814496 · 2025-09-08
RECRUITING
A Study of GV20-0251 in Advanced or Refractory Solid TumorsNCT07106827 · 2025-09-04
RECRUITING
IDOV-Immune for Advanced Solid TumorsNCT06910657 · 2025-08-25
RECRUITING
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043 · 2025-07-29
RECRUITING
Sample Collection for Ongoing Research and Product Evaluation StudyNCT07318051 · 2025-07-21
RECRUITING
Study of GV20-0251 in Participants With Solid Tumor MalignanciesNCT07070518 · 2025-07-11
RECRUITING
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)NCT06961006 · 2025-05-29
RECRUITING
An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid TumorsNCT06942143 · 2025-05-22
RECRUITING
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual DiseaseNCT06529822 · 2025-03-20
RECRUITING
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology ClinicsNCT06418204 · 2025-01-30
RECRUITING
Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)NCT06630611 · 2025-01-15
RECRUITING
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot TrialNCT06580002 · 2024-12-02
RECRUITING
Safety and Efficacy of BA1302 in Patients With Advanced Solid TumorsNCT06596915 · 2024-09-11
RECRUITING
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyNCT06362369 · 2024-08-23
RECRUITING
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLCNCT06332755 · 2024-06-05
RECRUITING
BostonGene and Exigent Genomic INsight StudyNCT06272864 · 2024-04-08
RECRUITING
A Study of IBI363 in Subjects with Advanced Solid MalignanciesNCT06281678 · 2024-04-08
RECRUITING
A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664 · 2024-03-19
RECRUITING
A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470 · 2024-03-06
RECRUITING
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478 · 2024-02-26
RECRUITING
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid TumorsNCT06265025 · 2024-02-20
RECRUITING
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell CarcinomaNCT05830058 · 2023-11-29
RECRUITING
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379 · 2023-11-01
RECRUITING
Safety and Efficacy of OBX-115 in Advanced Solid TumorsNCT06060613 · 2023-10-25
RECRUITING
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft TissueNCT05837767 · 2023-07-24
RECRUITING

Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.